Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates

Core Insights - Collegium Pharmaceutical (COLL) reported quarterly earnings of $2.25 per share, exceeding the Zacks Consensus Estimate of $1.88 per share, and showing an increase from $1.61 per share a year ago, resulting in an earnings surprise of +19.68% [1][2] - The company achieved revenues of $209.36 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.35% and up from $159.3 million year-over-year [2] - Collegium Pharmaceutical shares have increased approximately 25.1% year-to-date, outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of Collegium Pharmaceutical's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.10 on revenues of $197.79 million, and for the current fiscal year, it is $7.08 on revenues of $753.27 million [7] Industry Context - The Medical - Drugs industry, to which Collegium Pharmaceutical belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Metagenomi (MGX), is expected to report a quarterly loss of $0.60 per share, reflecting a year-over-year decline of -33.3%, with revenues projected at $9.26 million, down 19.6% from the previous year [9]